PURPOSE: The risk factor "large mediastinal tumor mass" is an internationally accepted unfavorable prognostic factor in the staging of Hodgkin's lymphoma (HL). The definition of this risk factor varies considerably between large cooperative study groups. The purpose of the present analysis was to determine to which degree data obtained from chest radiograph (CRX) give the same results as those from CT scans (CT). METHODS: A total of 145 de novo HL patients in early unfavorable and advanced stages were included in this study. A total of 94 patients had a large mediastinal tumor mass according to the guidelines of the German Hodgkin Study Group (GHSG), while 51 had mediastinal lymph node involvement only. The size of mediastinal involvement and the thoracic diameter were measured on CRX and CT. Agreement between CRX and CT was determined by sensitivity and specificity analysis as well as descriptive statistics and correlations. RESULTS: The correlation of the diameters on CRX with those of CT was 0.95 for the tumor size and 0.77 for the thoracic diameter. The diagnostic decision-large mediastinal mass or not-correlated with 0.81 between CRX and CT and was identical in 90.3% of cases. The sensitivity was 0.87 and the specificity 0.96 for CRX, which is considered the current standard. CONCLUSION: The results show that there is a high agreement between the measurements of CRX and CT. Diagnosis of a large mediastinal mass disagreed in 10% of patients. Since the correct diagnosis of this risk factor is decisive for the adequate multimodal treatment choice, CRX should not be omitted.
PURPOSE: The risk factor "large mediastinal tumor mass" is an internationally accepted unfavorable prognostic factor in the staging of Hodgkin's lymphoma (HL). The definition of this risk factor varies considerably between large cooperative study groups. The purpose of the present analysis was to determine to which degree data obtained from chest radiograph (CRX) give the same results as those from CT scans (CT). METHODS: A total of 145 de novo HL patients in early unfavorable and advanced stages were included in this study. A total of 94 patients had a large mediastinal tumor mass according to the guidelines of the German Hodgkin Study Group (GHSG), while 51 had mediastinal lymph node involvement only. The size of mediastinal involvement and the thoracic diameter were measured on CRX and CT. Agreement between CRX and CT was determined by sensitivity and specificity analysis as well as descriptive statistics and correlations. RESULTS: The correlation of the diameters on CRX with those of CT was 0.95 for the tumor size and 0.77 for the thoracic diameter. The diagnostic decision-large mediastinal mass or not-correlated with 0.81 between CRX and CT and was identical in 90.3% of cases. The sensitivity was 0.87 and the specificity 0.96 for CRX, which is considered the current standard. CONCLUSION: The results show that there is a high agreement between the measurements of CRX and CT. Diagnosis of a large mediastinal mass disagreed in 10% of patients. Since the correct diagnosis of this risk factor is decisive for the adequate multimodal treatment choice, CRX should not be omitted.
Authors: A Zabel-du Bois; S Nill; S Ulrich; U Oelfke; B Rhein; P Haering; S Milker-Zabel; A Schwahofer Journal: Strahlenther Onkol Date: 2012-01-05 Impact factor: 3.621
Authors: Andreas Engert; Annette Plütschow; Hans Theodor Eich; Andreas Lohri; Bernd Dörken; Peter Borchmann; Bernhard Berger; Richard Greil; Kay C Willborn; Martin Wilhelm; Jürgen Debus; Michael J Eble; Martin Sökler; Antony Ho; Andreas Rank; Arnold Ganser; Lorenz Trümper; Carsten Bokemeyer; Hartmut Kirchner; Jörg Schubert; Zdenek Král; Michael Fuchs; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Volker Diehl Journal: N Engl J Med Date: 2010-08-12 Impact factor: 91.245
Authors: Carsten Kobe; Markus Dietlein; Jeremy Franklin; Jana Markova; Andreas Lohri; Holger Amthauer; Susanne Klutmann; Wolfram H Knapp; Josee M Zijlstra; Andreas Bockisch; Matthias Weckesser; Reinhard Lorenz; Mathias Schreckenberger; Roland Bares; Hans T Eich; Rolf-Peter Mueller; Michael Fuchs; Peter Borchmann; Harald Schicha; Volker Diehl; Andreas Engert Journal: Blood Date: 2008-08-29 Impact factor: 22.113
Authors: Andreas Engert; Heinz Haverkamp; Carsten Kobe; Jana Markova; Christoph Renner; Antony Ho; Josée Zijlstra; Zdenek Král; Michael Fuchs; Michael Hallek; Lothar Kanz; Hartmut Döhner; Bernd Dörken; Nicole Engel; Max Topp; Susanne Klutmann; Holger Amthauer; Andreas Bockisch; Regine Kluge; Clemens Kratochwil; Otmar Schober; Richard Greil; Reinhard Andreesen; Michael Kneba; Michael Pfreundschuh; Harald Stein; Hans Theodor Eich; Rolf-Peter Müller; Markus Dietlein; Peter Borchmann; Volker Diehl Journal: Lancet Date: 2012-04-04 Impact factor: 79.321
Authors: Hans Theodor Eich; Volker Diehl; Helen Görgen; Thomas Pabst; Jana Markova; Jürgen Debus; Anthony Ho; Bernd Dörken; Andreas Rank; Anca-Ligia Grosu; Thomas Wiegel; Johann Hinrich Karstens; Richard Greil; Normann Willich; Heinz Schmidberger; Hartmut Döhner; Peter Borchmann; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Andreas Engert Journal: J Clin Oncol Date: 2010-08-16 Impact factor: 44.544
Authors: Ranjana H Advani; Fangxin Hong; Richard I Fisher; Nancy L Bartlett; K Sue Robinson; Randy D Gascoyne; Henry Wagner; Patrick J Stiff; Bruce D Cheson; Douglas A Stewart; Leo I Gordon; Brad S Kahl; Jonathan W Friedberg; Kristie A Blum; Thomas M Habermann; Joseph M Tuscano; Richard T Hoppe; Sandra J Horning Journal: J Clin Oncol Date: 2015-04-20 Impact factor: 44.544